Myasthenia gravis market to exceed $16B by 2036 driven by rising diagnoses and new targeted biologics.

The myasthenia gravis market, valued at around $6 billion in 2025, is projected to grow at a 9.1% CAGR to surpass $16 billion by 2036. Growth is fueled by increasing diagnosed cases, especially among older populations, and a surge in innovative targeted therapies such as IMVT-1402, Descartes-08, and FABHALTA. Advances in diagnostics and a shift towards precision immunotherapy are transforming treatment approaches, with several promising drugs in late-stage trials expected to accelerate market expansion. This evolving landscape highlights significant opportunities for improved patient outcomes and commercial growth in the autoimmune disease sector.